Clearmind’s Management Team Will Explain the Regulatory Process Required for Clearmind’s Patented MEAI Molecule to Become an FDA Approved Medicine...
KELOWNA, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
Coastal Medical Center Chooses Automated Coding Analysis for Inpatient and Outpatient Care to Improve Revenue Performance Atlanta, GA, Jan. 19,...
Live video webcast presentation on Wednesday, January 26th at 10:00 AM ETOCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM...
Will Deliver the First Quantum Solution for Medical Underwriting Edgewater, NJ, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Quad M solutions,...
New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods...
-- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI),...
Live video webcast presentation on Tuesday, January 25th at 3:00 PM ETISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook...
New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7...
In support of First Responders, Military Service Members and Boys and Girls Youth Groups MALIBU, CALIFORNIA, Jan. 19, 2022 (GLOBE...
- CX-904 is CytomX’s first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic -SOUTH SAN...
ATLANTA, Jan. 19, 2022 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and...
Keating brings strong experience as a life science executive and Board memberBOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a...
World’s first FDA-cleared portable MRI expands leading neurosurgery suite’s tech capabilities for novel diagnostic and therapeutic approachesGUILFORD, Conn. and MINNEAPOLIS,...
Leading Oral Care Company Has Teamed with Peloton Star Tunde Oyeneyin to Promote the Power of a Bright and Healthy...
Highlights: Seven subjects in cohort two intravenously dosed with RECCE® 327 (R327) at 150mg met all endpoints - indicating R327...
A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer Will Feature TOBI™ Discovery Platform and Lead Product Candidate, HCW9218MIRAMAR, Fla.,...
Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents...
Total FY2022 revenue anticipated to be in the range of $142 to $148 million Remains on track to achieve Adjusted...
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of...
